Press release
American Lung Association in California Hosts Inaugural Better Breathers Symposium in Costa Mesa for Lung Disease Patients
WHAT: American Lung Association Better Breathers SymposiumWHEN: Wednesday, October 25 from 9:30 a.m. to 2:00 p.m.
WHERE: Costa Mesa Senior Center – 695 W 19th St. Costa Mesa, CA 92627
COSTA MESA, CA (September 13, 2017) – The American Lung Association in California invites lung disease patients, their families, and caregivers to attend the inaugural Better Breathers Symposium in Costa Mesa on Wednesday, October 25, to learn more about managing chronic lung disease including asthma, chronic obstructive pulmonary disease (COPD), Alpha-1, and pulmonary fibrosis.
This free event offers physical activities to help patients improve breathing techniques and will also touch on topics such as The Benefits of Pulmonary Rehabilitation and Wellness, Lung Cancer: Prevention and Screening, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Advance Directives, and Asthma from presenting speakers within the Orange County lung health community: Richard Fischel, M.D. (Precision Thoracic, LLC), R. Bruce Moricca, M.D. (Newport Pulmonary Associates), David Pham, M.D. (Allianz Research Institute) Heba Ismail, M.D. and Cedric Rutland, M.D. (Pacific Pulmonary Medical Group), and Michael Rovzar, M.D. (Paloma Medical Group).
Breathing is something that people take for granted, but there are many who struggle to breathe every day. Lung disease is the third leading cause of death in the U.S., and is responsible for one in six deaths nationwide.
The Better Breathers Symposium aims to share innovations in the treatment and diagnosis of chronic lung diseases; provide a caring, fun, and supportive educational environment for patients; and increase awareness and local resources for a better quality of life.
Advanced registration is required and available on our website at action.lung.org/bbscostamesa.
For more information, please contact Jared Bigman at 714-332-3276 or Jared.Bigman@lung.org.
###
The American Lung Association in California is the leading organization working to save lives by improving lung health and preventing lung disease through research, education and advocacy. The Lung Association is focused on four strategic imperatives: to defeat lung cancer, to improve the air we breathe, to reduce the burden of lung disease on individuals and their families, and to eliminate tobacco use and tobacco-related diseases. For more information about the American Lung Association in California or to support the work it does, call 1-800-LUNGUSA (1-800-685-4872) or visit www.lung.org/california
American Lung Association in California
ATTN: Jared Bigman
513 E. First Street, Suite B
Tustin, CA 92780
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release American Lung Association in California Hosts Inaugural Better Breathers Symposium in Costa Mesa for Lung Disease Patients here
News-ID: 727316 • Views: …
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
